Cardiac amyloidosis is a subcategory of amyloidosis where there is the depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart’s atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function. The multisystemic disease was often misdiagnosed, with diagnosis previously occurring after death during the autopsy. However, recent advancements of technologies have increased the diagnosis of the disease. This disease has multiple types including light chain, familial, and senile. One of the most studied types is light chain cardiac amyloidosis. The prognosis depends on the extent of the deposits in the body and the type of amyloidosis.
- 1 Types
- 2 Symptoms
- 3 Cause
- 4 Diagnostic Tests
- 5 Prognosis
- 6 Treatments
- 7 References
- 8 External links
The formation of amyloid is due to these free light chains circulating through body caused by abnormal clones of plasma cells overproducing monoclonal immunoglobulin lambda light chains. This type usually affects males over the age of 60 and is rapidly progressive. Diagnostic tests includes serum and urine electrophoresis, laboratory testing for the determination of elevated levels of troponin and BNP, and ECGs showing low QRS voltages.
This type is caused by mutations of proteins involved in amyloid formation, including transthyretin (TTR), fibrinogen, apolipoprotein A1, or apolipoprotein A2. A common mutation is the TTR gene mutation Val122Ile. This type of amyloidosis can be identified by genetic testingfor protein mutation. Familial amyloidosis symptoms are centered around neuropathological and cardiac problems.
This type is considered the wild-type mutation which leads to the development of TTR deposits. It usually affects males over 70 years with the manifestation of carpal tunnel syndrome. This type is often misdiagnosed, however, greater use of cardiac magnetic resonance has increased diagnosing rates.
Symptoms of cardiac amyloidosis include dyspnea on exertion, peripheral edema, ascites, thromboembolisms, and symmetric, sensory neuropathy, postural hypotension, periorbital bleeding, pericardial effusion, atrial arrhythmia, first/second degree heart blocks, atrial fibrillation, syncope, elevated neck veins and jugular venous pressure.
The general cause of cardiac amyloidosis is misfolding of a specific protein precursor depending on the amyloidosis type. Protein precursors include immunoglobulin-derived light chains and transthyretin mutations. The misfolding of the protein causes it to have insoluble beta-pleated sheets, creating an amyloid. Amyloid, the aggregation, or clumping, of proteins, is resistant to degradation by the body. Amyloids are mostly fibrils, while also containing a P component, apolipoprotein, collagen, fibronectin, and laminin. The P component, a pentameric protein, stabilizes the fibrils of the amyloid, which reduces their clearance from the body. Deposits of the amyloids can occur through out of the body, including the heart, liver, kidneys, spleen, adrenal glands, and bones. Deposits in the extracellular cardiac space can stiffen the heart, resulting in restriction of the ventricles.
Echocardiography is used to provide an assessment of the heart’s function. Amyloidosis presents with ventricle and valvular thickening, biatrial enlargement, restrictive filling pattern, with normal to mildly reduced systolic function and decreased diastolic filling.
Echocardiography, can be used to help physicians with diagnosis, however, it can only be used for the suggesting of the disease not the confirmation, unless it is late stage amyloidosis.
ECGs of patients with cardiac amyloidosis usually show a low voltage in the limb leads with unusual, extreme right axis. There is usually a normal P-wave, however, it can be slightly prolonged. For patients with light-chain amyloidosis, the QRS complex pattern is skewed, with poor R-waves of the chest leads.
Laboratory tests including urea and creatinine levels, liver enzymes, glucose, thyroid function, full blood count, and clotting tests. The analysis of serum and urine for presence of monoclonal immunoglobulin is also done through immunofixation for detection of the monoclonal band. Presence of the monoclonal band would be consistent with light chain amyloidosis. For light chain amyloidosis, serum immunoglobulin free light chain assay can be used for diagnosis and following of the amyloidosis. In light-chain amyloidosis, a low paraprotein level can be present.
Extracardiac biopsies of tissues of the kidney, liver, peripheral nerve, or abdominal fat can be used to confirm the presence of amyloid deposits. Amyloid deposits in biopsy samples are confirmed through the use of Congo red dye, which produces a green birefringence when viewed under a polarized light. Sirius red staining or electron microscopyexamination can also be done. The determination of the type of amyloid can be done by immunohisto-labeling techniques, as well as, immunofluorescence staining.
Right heart catheterization is the test used to test for elevated diastolic ventricular pressures. This test is more invasive and would be performed after inconclusive endomyocardial biopsy samples.
Magnetic Resonance Imaging
Cardiac Magnetic Resonance Imaging
Scintigraphy can be used to measure the extent and distribution of the amyloid throughout the body, including the liver, kidney, spleen, and heart. A radiolabelled serum amyloid P component can be administered to a patient intravenously and the P component pools to the amyloid deposit proportional to the size of the deposit. The labelling of the P component can then be pictured by a gamma camera.
Prognosis of cardiac amyloidosis is correlated to the extent of the cardiac dysfunction. Usually the prognosis is not good and aggressive treatments are needed. Worse outcomes have been seen when echocardiography shows left ventricular wall thickness, poor systolic function and severe diastolic dysfunction.
For light-chain amyloidosis early detection leads to best possibility of therapies prolonging the period of remission. Prognosis can be made by looking at the levels of cardiac biomarkers troponin I, troponin T, BNP, and NT-proBNP.
Treatments differ according to type of amyloidosis present.
For light-chain amyloidosis, the use of FLC assays and NT-proBNP levels can be used to monitor the progression of amyloidosis and any response to treatments. Treatments targeting plasma cells to eliminate the misfolded free light chains can be done, such as chemotherapy for amyloidogenic plasma cell dyscrasia. Drugs can be prescribed including midodrine for autonomic neuropathy, amiodarone for patients with atrial fibrillation to prevent arrhythmias, and warfarin used after a cardioembolic episode. Beta-blockers should be avoided due to the usual symptom of hypotension. Treatments are also focused on treating the patient's heart failure.
- "Cardiac amyloidosis: A comprehensive review". Cor et Vasa. 55 (1): e60–e75. 2013-02-01. doi:10.1016/j.crvasa.2012.11.018. ISSN 0010-8650.
- Falk, Rodney H.; Alexander, Kevin M.; Liao, Ronglih; Dorbala, Sharmila (2016-09-20). "AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy". Journal of the American College of Cardiology. 68 (12): 1323–1341. doi:10.1016/j.jacc.2016.06.053. ISSN 0735-1097.
- Banypersad, Sanjay M.; Moon, James C.; Whelan, Carol; Hawkins, Philip N.; Wechalekar, Ashutosh D. (2012-04-24). "Updates in Cardiac Amyloidosis: A Review". Journal of the American Heart Association. 1 (2): e000364. doi:10.1161/JAHA.111.000364. ISSN 2047-9980. PMC . PMID 23130126.
- "Cardiac Amyloidosis: An Updated Review With Emphasis on Diagnosis and Future Directions". Current Problems in Cardiology. 43 (1): 10–34. 2018-01-01. doi:10.1016/j.cpcardiol.2017.04.003. ISSN 0146-2806.
- Falk, Rodney H.; Comenzo, Raymond L.; Skinner, Martha (25 September 1997). "The Systemic Amyloidoses". New England Journal of Medicine. 337 (13): 898–909. doi:10.1056/NEJM199709253371306. PMID 9302305.
- Gertz, Morie A.; Dispenzieri, Angela; Sher, Taimur (2014-10-14). "Pathophysiology and treatment of cardiac amyloidosis". Nature Reviews Cardiology. 12 (2): 91–102. doi:10.1038/nrcardio.2014.165. ISSN 1759-5002.